CliffBio
small molecule

BLOXIVERZ

NEOSTIGMINE METHYLSULFATE

Loss of exclusivity—loss of exclusivity
CompanyExela Pharma Sciences Llc →See this company's full patent-cliff portfolio

Drug detail

Brand nameBLOXIVERZ
Active ingredientNEOSTIGMINE METHYLSULFATE
Strength5MG/5ML (1MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusDISCN

More from Exela Pharma Sciences Llc

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.